[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"anaemia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:anaemia":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,43,75,98,127,153,179],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100584049","phase-3-comparing-high-and-low-dose-iron-treatments-for-people-on-peritoneal-dialysis-the-paladin-study-100584049",false,"NCT06884280","Comparing High and Low Dose Iron Treatments for People on Peritoneal Dialysis: The PALaDIN Study","Proactive High Dose Versus Low-dose Reactive Intravenous or Oral Iron in People on Peritoneal Dialysis (PALaDIN) - an Open-label, Feasibility Randomised Study","PALaDIN","Inclusion Criteria:\n\n* Males and females aged ≥18 years.\n* Able to give informed consent\n* Serum ferritin \\\u003C700ug\u002FL\n* Transferrin saturation level \\\u003C40%\n* No intravenous iron for last 4 weeks before randomisation (patients may be pre-identified and included after 4-week washout period)\n* Received maintenance peritoneal dialysis therapy for at least 4 weeks\n* Expected to remain on peritoneal dialysis therapy for duration of study\n\nExclusion Criteria:\n\n* Inadequate dialysis deemed by responsible clinician\n* Probability of need for transfusion within 1 week of enrolment\n* On or received a HIF-PHI in the past 4 weeks\n* Anticipated major surgery that the responsible clinician feels will impact response to treatment\n* Haemochromatosis \u002F haemosiderosis or ALT \\>x3 normal\n* Are deemed to be most suited to best-supportive or end-of-life care at time of screening\n* Women of childbearing potential not using effective means of contraception\n* Have been involved in another medicinal study (CTIMP) within past 4 weeks\n* Known allergy or adverse reaction to oral or intravenous iron preparations\n* CRP \\>50, TSATs \\>40%, SF \\>700 at time of recruitment\n* Active infection, HIV, active Hep B or C\n* Are unable or unwilling to consent to or complete the study procedures","ALL","18 Years",{"count":20,"type":21},30,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","Chronic kidney disease affects a significant portion of the UK population, with approximately 3.5 million adults diagnosed. At its most severe stage, end-stage kidney disease, individuals require frequent dialysis treatment. One form of dialysis, known as peritoneal dialysis, involves introducing and removing fluid from the abdominal cavity to help filter out toxins from the body.\n\nThe kidneys are involved in various hormonal processes, including those responsible for producing red blood cells, making anaemia a common consequence of kidney failure. When designing a clinical trial to evaluate the effectiveness of any treatment, it is essential to determine the number of suitable and willing participants, as well as those who can complete all required tests and measurements. Identifying the most appropriate measurement to assess the impact of intravenous iron (iron injected directly into veins) is crucial to ensure that any observed changes are meaningful to people with CKD and their carers. To address these considerations, the investigators will conduct a pilot feasibility trial.\n\nIn this trial, individuals with kidney disease undergoing peritoneal dialysis will be randomly assigned to receive either high-dose or low-dose intravenous iron, or oral iron therapy. Over twelve months, the investigators will monitor their anaemia response, symptoms of kidney disease, quality of life, physical performance (such as the ability to walk for six minutes), and cognitive function. Additionally, the investigators will assess the impact of each intervention on the frequency of blood transfusions, whether those on oral iron require intravenous iron, and any changes in the dosage of erythropoietin-stimulating agents (drugs that increase blood production).",[27,28,29],"Peritoneal Dialysis","Anaemia","Iron Deficiency, Anaemia","RECRUITING","2026-05-05",{"date":33,"type":34},"2026-05-06","ACTUAL",{"date":36,"type":34},"2025-11-13",{"date":38,"type":21},"2027-10",{"name":40,"class":41},"Hull University Teaching Hospitals NHS Trust","OTHER_GOV",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":22,"phases":53,"briefSummary":55,"conditions":56,"keywords":57,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":74},"100632093","scvo2-centered-optimisation-of-red-blood-cell-transfusions-100632093","NCT07509203","ScvO2-Centered Optimisation of RED Blood Cell Transfusions","ScvO2-Centered Optimisation of RED Blood Cell Transfusions (SCORED) - Protocol for a Multicenter, Randomised, Controlled Clinical Trial to Compare the Central Venous Saturation (ScvO2) Guided Transfusion Trigger Versus Transfusion Based on Clinician's Decision in the Critically Ill","SCORED","Inclusion Criteria:\n\n* Patient in medical\u002Fsurgical\u002Ftrauma ICU\n* Hemoglobin level between 7g\u002Fdl and 9g\u002Fdl\n* Written informed consent by patient or next of kin\n* Hemodynamically stable:\n\n  * CRT normal\n  * Serum lactate \\\u003C2 mmol\u002Fl\n  * MAP \\>65 mmHg\n  * noradrenalin \\\u003C 0,2 mcg\u002Fkg\u002Fmin and no increase in 6 hours\n  * No new ischemic change on ECG\n* Monitored with CVC, arterial catheter, hourly urine output\n* Respiratorily stable\n\n  * No support or\n  * Nasal canula\u002Fface mask O2 supplementation or\n  * NIV or\n  * Invasive mechanical ventillation: PC\u002FVC\u002FPS, PEEP\\\u003C 15 cmH2O FiO2 \\\u003C 50% and no increase in 6 hours\n* PiCCO or expert ECHO available within 48hours\n\nExclusion Criteria:\n\n* ScvO2\\>80%\n* Acid-base imbalance (pH\\\u003C7.3 or pH\\>7.5)\n* Chronic kidney disease (KDIGO Stage 3-4-5)\n* Acute heart failure (ESC 2021 definition)\n* Pregnancy\n* Active bleeding\n* Neurotrauma requiring intracranial pressure monitoring\n* Morbid obesity BMI \\>40\n* Horowitz Quotient (paO2\u002FFiO2) \\\u003C 200\n* Acute and chronic liver failure (Child-Pugh B,C)\n* Fever",{"count":52,"type":21},600,[54],"NA","This clinical trial aims to personalise red blood cell transfusion strategies in the crtitically ill patients. The amount of transfusions needs to be minimised in order to prevent adverse events and organ dysfunctions linked to high amounts of red blood cell transfusions.\n\nThe researchers aim to investigate the efficacy and safety of measuring the central venous oxygen saturation (ScvO2) (oxygen content in a venous blood sample taken from a central line) to guide clinicians if transfusion is necessary.\n\nThe researchers aim to compare the ScvO2 guided transfusion strategy with transfusion based on the clinician's judgment (taking into consideration the patients' comorbidities and actual vital parameters).",[28],[58,59,60,61,62],"central venous saturation","transfusion","critically ill","ICU","red blood cell","NOT_YET_RECRUITING","2026-03-28",{"date":66,"type":34},"2026-04-03",{"date":68,"type":21},"2026-04-15",{"date":70,"type":21},"2029-04",{"name":72,"class":73},"Semmelweis University","OTHER",2,{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":4,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":82,"enrollmentInfo":83,"targetDuration":4,"studyType":22,"phases":85,"briefSummary":86,"conditions":87,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":4},"100616015","phase-3-a-study-to-evaluate-efficacy-and-safety-of-qlg1218daprodustat-in-chinese-hemodialysis-hd-dependent-subjects-with-anemia-associated-with-chronic-kidney-disease-ckd-100616015","NCT07300111","A Study to Evaluate Efficacy and Safety of QLG1218(Daprodustat) in Chinese Hemodialysis (HD)-Dependent Subjects With Anemia Associated With Chronic Kidney Disease (CKD)","A Randomized, Open Label, Active-controlled, Parallel-group, Multi-center Study to Evaluate Efficacy and Safety of QLG1218(Daprodustat) in Chinese Hemodialysis-dependent Subjects With Anemia Associated With Chronic Kidney Disease.","Inclusion Criteria:\n\n1. Female or male，age 18 to 75\n2. Weight 45 to 100 kg\n3. Receiving hemodialysis (including hemodiafiltration) consistently three times a week for at least 12 weeks prior to screening.\n4. Patients with pre-dialysis Hb levels measured after the maximum interdialytic interval at Scr Visit 1 and Scr Visit 2 (1 week after the start of observation) of ≥95 g\u002FL and \\\u003C120 g\u002FL and a difference (in absolute value) between Scr Visit 1 and Scr Visit 2 of ≤15 g\u002FL.\n5. TSAT \\>20% and ferritin \\>100 μg\u002FL\n6. Use of one and the same ESA for 10 weeks prior to screening\n7. Darbepoetin alfa 10 to 60 μg per week, epoetin (including biosimilars) 1500 to 10000 international units (IU) per week.\n\nExclusion Criteria:\n\n1. History of bone-marrow hypoplasia, pure red cell aplasia, pernicious anemia, thalassemia, sickle cell anemia, or myelodysplastic syndromes.\n2. History of malignancy.\n3. Evidence of actively bleeding gastric, duodenal, or esophageal ulcer disease OR clinically significant GI bleeding within 12 weeks prior to screening or during a period from screening to Day 1.\n4. Myocardial infarction, acute coronary syndrome, stroke, or transient ischemic attack: Diagnosed within 12 weeks prior to screening or during a period from screening to Day 1\n5. Chronic Class III or IV heart failure, as defined by the New York Heart Association (NYHA) functional classification system.\n6. poorly controlled hypertension.\n7. Current unstable active liver or biliary disease.\n8. History of severe allergic or anaphylactic reactions or hypersensitivity to excipients in the investigational product.\n9. Use or planned use of any prescription or non-prescription drugs or dietary supplements that are prohibited during the study period.\n10. Use of an investigational agent within 30 days or five half lives of the investigational agent (whichever is longer)\n11. Use of daprodustat or other HIF-PHI within 4 weeks prior to screening, or any prior treatment with daprodustat for a treatment duration of \\> 4weeks.\n12. QTc \\>500 milliseconds (msec); or QTc \\>530 msec in subjects with bundle branch block.\n13. ALT or AST \\>2 upper limit of normal (ULN)，or bilirubin \\>1.5×ULN.","75 Years",{"count":84,"type":21},100,[24],"This study is to evaluate the efficacy and safety of QLG1218(daprodustat) following a switch from erythropoiesis-stimulating agent (ESA) in Chinese HD subjects with renal anemia who are currently treated with ESA. The primary objective is to demonstrate non-inferiority of QLG1218 to darbepoetin alfa. This study is a randomized, open Label, active-controlled, parallel-group, multi-center Study. The total duration of the study will be approximately 32 weeks including screening and follow-up.",[28],"2025-12-10",{"date":90,"type":34},"2025-12-23",{"date":92,"type":21},"2025-12-31",{"date":94,"type":21},"2027-07",{"name":96,"class":97},"Qilu Pharmaceutical Co., Ltd.","INDUSTRY",{"id":99,"slug":100,"hasResults":11,"nctId":101,"briefTitle":102,"officialTitle":103,"acronym":4,"eligibilityCriteria":104,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":105,"enrollmentInfo":106,"targetDuration":4,"studyType":22,"phases":108,"briefSummary":109,"conditions":110,"keywords":113,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":4},"100615710","phase-3-probiotics-against-erythropoietin-resistance-in-chronic-kidney-disease-patients-100615710","NCT07296146","Probiotics Against Erythropoietin Resistance in Chronic Kidney Disease Patients.","Effect of Probiotic Supplementation on Resistant Anaemia to Erythropoietin in Chronic Kidney Disease Patients.","Inclusion Criteria:\n\n* Adult patients with end stage renal disease for more than 3 months on regular hemodialysis (GFR less than 15 ml\u002Fmin\u002Fm2\n* Receiving stable doses of erythropoietin therapy\n* Able and willing to provide informed consent\n\nExclusion Criteria:\n\n* Recent probiotic, antibiotic, or immunosuppressive therapy\n* Microcytic hypochromic anemia.\n* Patients with hyperparathyroidism\n* Recent or planned kidney transplantation Gastrointestinal disorders (active IBD, cancer)\n* Pregnancy or lactation\n* Severe comorbidities (e.g., active infection, malignancies)\n* Cognitive or physical inability to comply with protocol","65 Years",{"count":107,"type":21},80,[24],"The goal of this clinical trial is to assess whether probiotic supplementation can improve the hematological response of CKD patients to erythropoietin therapy and prevent or reduce erythropoietin resistance. The main questions it aims to answer are:\n\nCan probiotic be used as an adjuvant strategy in anemia management and increasing ESA responsiveness in CKD? What medical problems do participants have when taking probiotic? Researchers will compare Erythropoietin only with Erythropoietin + Probiotic to see if Probiotic aids in treating anaemic chronic kidney disease patients.\n\nParticipants will:\n\nTake Erythropoietin + Probiotic or Probiotic only every day for 3 months Visit the clinic once every 4 weeks for checkups and tests Keep a diary of their symptoms",[28,111,112],"Chronic Kidney Disease","Regular Hemodialysis",[114,115,116,117],"Probiotic","erythropoietin","resistant anaemia","chronic kidney disease patients","2025-12-08",{"date":120,"type":34},"2025-12-22",{"date":122,"type":21},"2025-12-15",{"date":124,"type":21},"2026-05-15",{"name":126,"class":73},"Badr University",{"id":128,"slug":129,"hasResults":11,"nctId":130,"briefTitle":131,"officialTitle":132,"acronym":4,"eligibilityCriteria":133,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":134,"targetDuration":4,"studyType":136,"phases":4,"briefSummary":137,"conditions":138,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":144,"lastUpdatePostDateStruct":145,"startDateStruct":147,"completionDateStruct":149,"leadSponsor":151,"locationsCount":42},"100593578","robot-assisted-cystectomies-with-regard-to-blood-loss-pain-and-transfusions-100593578","NCT07008261","Robot-assisted Cystectomies With Regard to Blood Loss, Pain and Transfusions.","Prospective Evaluation of Robot-assisted Cystectomies With Regard to Blood Loss, Pain and Transfusion Requirements.","Inclusion Criteria:\n\n* planned radical cystectomy\n\nExclusion Criteria:\n\n* ASA classification V\n* Previously known coagulation disorder",{"count":135,"type":21},60,"OBSERVATIONAL","What influence does robot-assisted surgical treatment in the sense of a radical cystectomy and possibly bladder reconstruction have on blood loss, pain and transfusion requirements? We intend to conduct a corresponding prospective observational study at a tertiary centre.",[139,140,141,28,142,143],"Transfusions","Cystectomy","Blood Loss Requiring Transfusion","Anaemia Postoperative","Pain, Postoperative","2025-08-25",{"date":146,"type":34},"2025-09-02",{"date":148,"type":34},"2025-08-01",{"date":150,"type":21},"2027-12-31",{"name":152,"class":73},"Goethe University",{"id":154,"slug":155,"hasResults":11,"nctId":156,"briefTitle":157,"officialTitle":158,"acronym":4,"eligibilityCriteria":159,"healthyVolunteers":11,"sex":17,"minAge":160,"maxAge":4,"enrollmentInfo":161,"targetDuration":4,"studyType":22,"phases":163,"briefSummary":164,"conditions":165,"keywords":167,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":170,"lastUpdatePostDateStruct":171,"startDateStruct":173,"completionDateStruct":175,"leadSponsor":177,"locationsCount":42},"100593291","the-mcce-vs-egd-trial-100593291","NCT07004530","the MCCE vs EGD Trial","Magnetically Controlled Capsule Endoscopy vs Esophago-gastro-Duodenoscopy as The Initial Investigation for Anaemia in Patients With Acute Coronary Syndrome (the MCCE vs EGD Trial) - a Single Centre Randomized Study","Inclusion Criteria:\n\nsubjects are patients older than 18 years old with:\n\n1. the diagnosis of ACS as defined by symptoms of chest pain or shortness-of-breath, abnormal electrocardiogram and positive enzyme, requiring coronary intervention\n2. new-onset anaemia as defined by Hb\\\u003C11 g\u002FdL on admission blood taking\n\nExclusion Criteria:\n\n1. History of active haematological disease including hemoglobinopathies such as thalassemia, Myelodysplastic syndromes, haematological malignancy, aplastic anaemia, or autoimmune haemolytic anaemia.\n2. Patients with known active gastrointestinal malignancy.\n3. Contraindications for CE: suspected or known gastrointestinal obstruction, stenosis, fistula, diverticula, presence of gastrointestinal obstruction symptoms such as pain or dysphagia; inoperative conditions or refusal to undergo abdominal surgery if required; history of laparotomy, gastric or bowel surgery; presence of metallic implants that is not MRI conditional.\n4. Contraindications for EGD: Possible gastrointestinal perforation, medically unstable patients, patient with known pharyngeal diverticulum, and patients with recent head and neck trauma.\n5. Inability to take 1-month DAPT such as non-deferrable surgery within 1 months, severe allergy or hypersensitivity reaction to aspirin or P2Y12 inhibitors, or patients in whom 1 months DAPT is not indicated.\n6. Patients whose life-expectancy is less than 6 months.\n7. Patients who are pregnant or lactating.\n8. Patients who are unable to give informed consent.\n9. Patients who are in active heart failure or fluid-overload state.\n10. Patients who have chronic renal failure as defined by estimated glomerular filtration rate \\\u003C15 ml\u002Fmin\u002F1.73m2.","19 Years",{"count":162,"type":21},238,[54],"Anaemia is common in patients with acute coronary syndrome (ACS) and is associated with significant recurrent bleeding risk and major adverse cardiovascular event (MACE). Esophageal-gastro-Duodenoscopy (EGD) is commonly used as an initial investigation for anaemia but is often non-diagnostic. Magnetically Controlled Capsule Endoscopy (MCCE) being less invasive and with comparable diagnostic accuracy as EGD, might be used as an alternative initial investigation for anaemia in patients with ACS.",[28,166],"Acute Coronary Syndrome",[168,169],"Capsule Endoscopy","Esophago-gastro-Duodenoscopy","2025-05-27",{"date":172,"type":34},"2025-06-04",{"date":174,"type":21},"2025-09-24",{"date":176,"type":21},"2027-11-24",{"name":178,"class":73},"Chinese University of Hong Kong",{"id":180,"slug":181,"hasResults":11,"nctId":182,"briefTitle":183,"officialTitle":184,"acronym":4,"eligibilityCriteria":185,"healthyVolunteers":11,"sex":17,"minAge":186,"maxAge":18,"enrollmentInfo":187,"targetDuration":4,"studyType":22,"phases":189,"briefSummary":190,"conditions":191,"keywords":193,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":197,"lastUpdatePostDateStruct":198,"startDateStruct":200,"completionDateStruct":202,"leadSponsor":204,"locationsCount":4},"100573751","study-on-effect-of-papworth-technique-in-anemic-asthmatic-pediatrics-100573751","NCT06750354","Study on Effect of Papworth Technique in Anemic Asthmatic Pediatrics","A Randomized Controlled Study to Evaluate the Effect of Papworth Technique and Aerobic Training on Hemoglobin and Exercise Tolerance in Anemic Asthmatic Pediatrics","Inclusion Criteria:\n\nPatients will be included:\n\n1. 40 patients from both genders.\n2. Participants between the age 12 and 18 years\n3. Oriented, medically stable and taking their medical treatment\n4. Mild and moderate asthma\n5. All patients are diagnosed as iron deficiency anemia\n6. Body mass index between 18.5 -24.9\n\nExclusion Criteria:\n\n1\\. Have any serious chest diseases, Patients with heart diseases. 2. Patients with neurological disease affecting respiratory muscles or any muscular dystrophy 3. Patients with kidney diseases 4. Patients with liver diseases 5. Other types of anaemia Chest deformities\n\n\\-","12 Years",{"count":188,"type":21},40,[54],"As asthma is chronic condition which interferes with quality of life and exercise tolerance, so it is important to find out cost-effective alternative for the management of asthma due to increased prevalence and rising health care cost as well . Therefore, to provide comprehensive asthma treatment, it is necessary to rule out and address the factor affecting quality of life and exercise tolerance. Asthmatics require stepwise approach which contains assessment treatment planning and review of response. Along with this modification of risk factors, controller therapy is adjusted accordingly. But this is inadequate for asthma management as pharmacological management has some side effects. So, in addition to medical care, Papworth method provides good adjuvant to control asthma symptoms. Asthma subjects require comprehensive approach to deal with these hyperinflation and hyperventilation which are common manifestations of asthma",[28,192],"Asthma Exacerbations",[194,195,196],"papworth technique","aerobic training","anaemic asthmatic pediatrics","2024-12-24",{"date":199,"type":34},"2024-12-27",{"date":201,"type":21},"2024-12-20",{"date":203,"type":21},"2025-03-15",{"name":205,"class":73},"Cairo University"]